Hims & Hers Health, Inc. (NYSE: HIMS) has caught the attention of investors. Recently, Truist Securities dropped its price target for the stock from $48 to $37 but kept a “Hold” rating. This week, the stock dipped by 8%. Still, it’s impressive that the stock has surged by 195% over the past year, currently sitting at around $46.02.
Hims & Hers focuses on personalized healthcare. They connect patients with licensed professionals through a digital platform. Their services cover important areas like sexual health, mental health, dermatology, and primary care. This makes healthcare more accessible, especially for those who prefer online visits.
Despite its potential, some experts suggest that other tech stocks, particularly in AI, could offer better returns with less risk. According to recent trends, investors are increasingly attracted to AI due to its rapid growth in various sectors.
In terms of revenue, Truist anticipates modest growth in the coming quarters, partly thanks to deferred revenue and the Zava acquisition. However, they raised concerns about future growth, focusing more on revenue sources than on app downloads or user engagement.
A survey by Deloitte found that about 75% of consumers are open to using telehealth tools. This indicates a growing acceptance of digital health services. However, as more companies enter this space, competition will increase.
As Hims & Hers navigates these changes, keeping an eye on new developments in telehealth and AI is essential. This landscape is evolving quickly, and staying informed can help investors make better choices.
For more insights, check latest reports from trusted sources like the CDC or NIH on telehealth trends and consumer behavior.
Source link
Hims & Hers Health, Inc., deferred revenue, Hims & Hers
